Moving from Malaria Burden Reduction toward Elimination: An Evaluation of Mass Drug Administration in Southern Province, Zambia

John M Miller, Thomas P Eisele, Maya S Fraser, Manuel T Lewis, Laurence Slutsker, Elizabeth Chizema Kawesha, John M Miller, Thomas P Eisele, Maya S Fraser, Manuel T Lewis, Laurence Slutsker, Elizabeth Chizema Kawesha

Abstract

From December 2014 to February 2016, a cluster randomized controlled trial was carried out in 60 health facility catchment areas along Lake Kariba in Zambia's Southern Province. The trial sought to evaluate the impact of four rounds of a mass drug administration (MDA) intervention with dihydroartemisinin-piperaquine (DHAP) or focal MDA with DHAP at the household level compared with a control population that received the standard of care. This study was the first randomized controlled trial with DHAP for MDA in sub-Saharan Africa and was conducted through a collaboration between the National Malaria Elimination Programme in the Zambian Ministry of Health, the PATH Malaria Control and Elimination Partnership in Africa, and the Center for Applied Malaria Research and Evaluation at Tulane University. This article serves as an introduction to a collection of articles designed to explore different aspects of the intervention. By describing the recent history of malaria control in Zambia leading up to the trial-from the scale-up of point-of-care diagnosis and treatment, vector control, and indoor residual spraying early in the twenty-first century, to the efforts made to sustain the gains achieved with that approach-it provides a rationale for the implementation of a trial that has informed a new national strategic plan and solidified malaria elimination as Zambia's national goal.

Conflict of interest statement

Disclosure: All authors had full access to all the data in the study.

Disclaimer: The funding source had no role in the conduct, analysis, or interpretation of results of the study.

References

    1. Zambia Ministry of Health , 2006. A Road Map for Impact on Malaria in Zambia 2006–2010: A 5-Year Strategic Plan. Lusaka, Zambia: Zambia Ministry of Health.
    1. Agha S, Van Rossem R, Stallworthy G, Kusanthan T, 2007. The impact of a hybrid social marketing intervention on inequities in access, ownership and use of insecticide-treated nets. Malar J 6: 13.
    1. Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Moonga H, Banda P, Okorosobo T, 2007. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J 6: 21.
    1. Steketee RW, Sipilanyambe N, Chimumbwa J, Banda JJ, Mohamed A, Miller J, Basu S, Miti SK, Campbell CC, 2008. National malaria control and scaling up for impact: the Zambia experience through 2006. Am J Trop Med Hyg 79: 45–52.
    1. Roll Back Malaria , 2011. Focus on Zambia. Geneva, Switzerland: World Health Organization; Progress & Impact Series Country Reports No. 2.
    1. Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW, 2007. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J 6: 31.
    1. Chizema-Kawesha E, Miller JM, Steketee RW, Mukonka VM, Mukuka C, Mohamed AD, Miti SK, Campbell CC, 2010. Scaling up malaria control in Zambia: progress and impact 2005–2008. Am J Trop Med Hyg 83: 480–488.
    1. Zambia Ministry of Health , 2010. Zambia National Malaria Programme Performance Review 2010. Lusaka, Zambia: Ministry of Health.
    1. Zambia Ministry of Health , 2015. National Malaria Control Programme Strategic Plan for FY 2011–2016: Consolidating Malaria Gains for Impact in National Malaria Strategic Plan. Lusaka, Zambia: Zambia Ministry of Health.
    1. Zambia Ministry of Health , 2011. National Human Resources for Health Strategic Plan 2011–2015. Lusaka, Zambia: Ministry of Health.
    1. Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F, 2011, Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management. Malar J 10: 159.
    1. Shelley KD, Belete YW, Phiri SC, Musonda M, Kawesha EC, Muleya EM, Chibawe CP, van den Broek JW, Vosburg KB, 2016. Implementation of the community health assistant (CHA) cadre in Zambia: a process evaluation to guide future scale-up decisions. J Community Health 41: 398–408.
    1. Lusaka Times , 2015. Construction of 650 Health Posts on Course for Completion Next Year. Lusaka, Zambia: Lusaka Times.
    1. Seidenberg PD, Hamer DH, Iyer H, Pilingana P, Siazeele K, Hamainza B, MacLeod WB, Yeboah-Antwi K, 2012. Impact of integrated community case management on health-seeking behavior in rural Zambia. Am J Trop Med Hyg 87 (Suppl 5): 105–110.
    1. Larsen DA, Winters A, Cheelo S, Hamainza B, Kamuliwo M, Miller JM, Bridges DJ, 2017. Shifting the burden or expanding access to care? Assessing malaria trends following scale-up of community health worker malaria case management and reactive case detection. Malar J 16: 441.
    1. Strachan C, Wharton-Smith A, Sinyangwe C, Mubiru D, Ssekitooleko J, Meier J, Gbanya M, Tibenderana JK, Counihan H, 2014. Integrated community case management of malaria, pneumonia and diarrhoea across three African countries: a qualitative study exploring lessons learnt and implications for further scale up. J Glob Health 4: 020404.
    1. Zambia Ministry of Health , 2010. Zambia National Malaria Indicator Survey 2010. Lusaka, Zambia: Ministry of Health.
    1. Zambia Ministry of Health , 2012. Zambia National Malaria Indicator Survey 2012. Lusaka, Zambia: Ministry of Health.
    1. Zambia Ministry of Health , 2008. Zambia National Malaria Indicator Survey 2008. Lusaka, Zambia: Ministry of Health.
    1. von Seidlein L, Dondorp A, 2015. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti Infect Ther 13: 715–730.
    1. White NJ, 2016. Does antimalarial mass drug administration increase or decrease the risk of resistance? Lancet Infect Dis 17: e15–e20.
    1. von Seidlein L, Greenwood BM, 2003. Mass administrations of antimalarial drugs. Trends Parasitol 19: 452–460.
    1. Poirot E, Skarbinski J, Sinclair D, Kachur S, Slutsker L, Hwang J, 2013. Administration of antimalarial drugs to whole populations. Cochrane Database Syst Rev 12: CD008846.
    1. Bretscher MT, Griffin JT, Ghani AC, Okell LC, 2017. Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment. Malar J 16: 341.
    1. Brady OJ, et al. 2017. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health 5: e680–e687.
    1. Larsen DA, Bennett A, Silumbe K, Hamainza B, Yukich JO, Keating J, Littrell M, Miller JM, Steketee RW, Eisele TP, 2015. Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design. Am J Trop Med Hyg 92: 913–921.
    1. Cook J, et al. 2019. Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis 211: 1476–1483.
    1. Stresman GH, et al. 2015. Focal screening to identify the subpatent parasite reservoir in an area of low and heterogeneous transmission in the Kenya highlands. J Infect Dis 212: 1768–1777.
    1. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ, 2012. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 3: 1237.
    1. McMorrow ML, Aidoo M, Kachur SP, 2011. Malaria rapid diagnostic tests in elimination settings—can they find the last parasite? Clin Microbiol Infect 17: 1624–1631.
    1. Eisele TP, et al. 2020. Impact of four rounds of mass drug administration with dihydroartemisinin-piperaquine implemented in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 7–18.
    1. Silumbe K, et al. 2020. Assessment of the acceptability of testing and treatment during a mass drug administration trial for malaria in Zambia using mixed methods. Am J Trop Med Hyg 103 (Suppl 2): 28–36.
    1. Finn TP, et al. 2020. Treatment coverage estimation for mass drug administration for malaria with dihydroartemisin-piperaquine in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 19–27.
    1. Finn TP, et al. 2020. Adherence to mass drug administration with dihydroartemisinin-piperaquine and Plasmodium falciparum clearance in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 37–45.
    1. Chishimba S, et al. 2020. Prevalence of Plasmodium falciparum and non-falciparum infections by photo-induced electron transfer–PCR in a longitudinal cohort of individuals enrolled in a mass drug administration trial in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 82–89.
    1. Bennett A, et al. 2020. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 54–65.
    1. Daniels RF, et al. 2020. Evidence for reduced malaria parasite population after application of population-level antimalarial drug strategies in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 66–73.
    1. Porter TR, et al. 2020. Recent travel history and Plasmodium falciparum malaria infection in a region of heterogenous transmission in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 74–81.
    1. Chanda J, et al. 2020. Pyrethroid and carbamate resistance in Anopheles funestus giles along Lake Kariba in southern Zambia. Am J Trop Med Hyg 103 (Suppl 2): 90–97.
    1. Yukich JO, et al. 2020. Cost-effectiveness of focal mass drug administration and mass drug administration with dihydroartemisinin-piperaquine for malaria prevention in Southern Province, Zambia: results of a community-randomized controlled trial. Am J Trop Med Hyg 103 (Suppl 2): 46–53.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa